Integration of Regulatory Networks by NKX3-1 Promote Cancer Survival

Molecular and Cellular Biology 32, 399-414 DOI: 10.1128/mcb.05958-11

Citation Report

#	Article	IF	CITATIONS
1	Novel functions for Rab GTPases in multiple aspects of tumour progression. Biochemical Society Transactions, 2012, 40, 1398-1403.	1.6	72
2	FoxA1 is a Key Mediator of Hormonal Response in Breast and Prostate Cancer. Frontiers in Endocrinology, 2012, 3, 68.	1.5	73
3	Prevalent Glucocorticoid and Androgen Activity in US Water Sources. Scientific Reports, 2012, 2, 937.	1.6	51
4	Oxidative stress in apoptosis and cancer: an update. Archives of Toxicology, 2012, 86, 1649-1665.	1.9	290
5	Antioxidant Treatment Promotes Prostate Epithelial Proliferation in Nkx3.1 Mutant Mice. PLoS ONE, 2012, 7, e46792.	1.1	17
6	Transcriptional network of androgen receptor in prostate cancer progression. International Journal of Urology, 2013, 20, 756-768.	0.5	57
7	Sequencing the transcriptional network of androgen receptor in prostate cancer. Cancer Letters, 2013, 340, 254-260.	3.2	15
8	A high-resolution map of the three-dimensional chromatin interactome in human cells. Nature, 2013, 503, 290-294.	13.7	1,074
9	Distinct Gene Expression Profiles of Viral- and Nonviral-Associated Merkel Cell Carcinoma Revealed by Transcriptome Analysis. Journal of Investigative Dermatology, 2013, 133, 936-945.	0.3	98
10	Functional Activation of ATM by the Prostate Cancer Suppressor NKX3.1. Cell Reports, 2013, 4, 516-529.	2.9	33
11	Translational Bioinformatics for Diagnostic and Prognostic Prediction of Prostate Cancer in the Next-Generation Sequencing Era. BioMed Research International, 2013, 2013, 1-13.	0.9	34
12	FoxA1 Specifies Unique Androgen and Glucocorticoid Receptor Binding Events in Prostate Cancer Cells. Cancer Research, 2013, 73, 1570-1580.	0.4	194
13	The ETS Domain Transcription Factor ELK1 Directs a Critical Component of Growth Signaling by the Androgen Receptor in Prostate Cancer Cells. Journal of Biological Chemistry, 2013, 288, 11047-11065.	1.6	57
14	NKX3.1 is expressed in ER-positive and AR-positive primary breast carcinomas. Journal of Clinical Pathology, 2014, 67, 768-771.	1.0	27
15	Androgen receptor co-regulatory networks in castration-resistant prostate cancer. Endocrine-Related Cancer, 2014, 21, R1-R11.	1.6	19
16	Integrative Analysis of FOXP1 Function Reveals a Tumor-Suppressive Effect in Prostate Cancer. Molecular Endocrinology, 2014, 28, 2012-2024.	3.7	56
17	Essential Roles of Epithelial Bone Morphogenetic Protein Signaling During Prostatic Development. Endocrinology, 2014, 155, 2534-2544.	1.4	13
18	Large-Scale Quality Analysis of Published ChIP-seq Data. G3: Genes, Genomes, Genetics, 2014, 4, 209-223.	0.8	125

#	Article	IF	CITATIONS
19	Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. BMC Cancer, 2014, 14, 16.	1.1	25
20	miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family. Journal of Translational Medicine, 2014, 12, 17.	1.8	64
21	Differential Effects of RUNX2 on the Androgen Receptor in Prostate Cancer: Synergistic Stimulation of a Gene Set Exemplified by SNAI2 and Subsequent Invasiveness. Cancer Research, 2014, 74, 2857-2868.	0.4	30
22	NFI Transcription Factors Interact with FOXA1 to Regulate Prostate-Specific Gene Expression. Molecular Endocrinology, 2014, 28, 949-964.	3.7	70
23	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	9.4	408
24	Constitutive Activity of the Androgen Receptor. Advances in Pharmacology, 2014, 70, 327-366.	1.2	47
25	Studying forkhead box protein A1–DNA interaction and ligand inhibition using gold nanoparticles, electrophoretic mobility shift assay, and fluorescence anisotropy. Analytical Biochemistry, 2014, 448, 95-104.	1.1	6
26	Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer. International Journal of Biological Sciences, 2014, 10, 614-619.	2.6	58
27	The oxidative demethylase ALKBH3 marks hyperactive gene promoters in human cancer cells. Genome Medicine, 2015, 7, 66.	3.6	15
28	The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. BMC Cancer, 2015, 15, 791.	1.1	29
29	Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci. Prostate, 2015, 75, 1264-1276.	1.2	37
30	FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells. Prostate, 2015, 75, 976-987.	1.2	22
31	RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. Oncotarget, 2015, 6, 2263-2276.	0.8	75
32	High expression of small GTPase Rab3D promotes cancer progression and metastasis. Oncotarget, 2015, 6, 11125-11138.	0.8	82
33	Lagging-strand replication shapes the mutational landscape of the genome. Nature, 2015, 518, 502-506.	13.7	213
34	Ligand-Dependent Enhancer Activation Regulated by Topoisomerase-I Activity. Cell, 2015, 160, 367-380.	13.5	122
35	The IncRNA <i>DRAIC</i> / <i>PCAT29</i> Locus Constitutes a Tumor-Suppressive Nexus. Molecular Cancer Research, 2015, 13, 828-838.	1.5	119
37	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Human Molecular Genetics, 2015, 24, 5603-5618.	1.4	50

#	Article	IF	CITATIONS
38	Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. Molecular Endocrinology, 2015, 29, 1426-1439.	3.7	22
39	TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nature Communications, 2015, 6, 8219.	5.8	93
40	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	1.4	67
41	Feed-forward transcriptional programming by nuclear receptors: Regulatory principles and therapeutic implications. , 2015, 145, 85-91.		15
42	Coagulation factor VII is regulated by androgen receptor in breast cancer. Experimental Cell Research, 2015, 331, 239-250.	1.2	16
43	Genes and pathways identified in thyroid carcinoma based on bioinformatics analysis. Neoplasma, 2016, 63, 559-568.	0.7	12
44	Identification of an <i>AR</i> Mutation-Negative Class of Androgen Insensitivity by Determining Endogenous AR Activity. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 4468-4477.	1.8	64
45	Incorporating Functional Annotations for Fine-Mapping Causal Variants in a Bayesian Framework Using Summary Statistics. Genetics, 2016, 204, 933-958.	1.2	51
46	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nature Genetics, 2016, 48, 1142-1150.	9.4	196
47	NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discovery, 2016, 2, 16041.	3.1	41
48	Refinement of the androgen response element based on ChIP-Seq in androgen-insensitive and androgen-responsive prostate cancer cell lines. Scientific Reports, 2016, 6, 32611.	1.6	97
49	Regulating NKX3.1 stability and function: Post-translational modifications and structural determinants. Prostate, 2016, 76, 523-533.	1.2	19
50	Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth. Oncogene, 2016, 35, 6350-6358.	2.6	41
51	Understanding transcriptional regulatory networks using computational models. Current Opinion in Genetics and Development, 2016, 37, 101-108.	1.5	34
52	The emerging role of noncoding RNA in prostate cancer progression and its implication on diagnosis and treatment. Briefings in Functional Genomics, 2016, 15, 257-265.	1.3	17
53	Assembly of methylated KDM1A and CHD1 drives androgen receptor–dependent transcription and translocation. Nature Structural and Molecular Biology, 2016, 23, 132-139.	3.6	70
54	Comparing the rules of engagement of androgen and glucocorticoid receptors. Cellular and Molecular Life Sciences, 2017, 74, 2217-2228.	2.4	51
55	Computational identification of mutually exclusive transcriptional drivers dysregulating metastatic microRNAs in prostate cancer. Nature Communications, 2017, 8, 14917.	5.8	16

#	Article	IF	CITATIONS
56	Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development (Cambridge), 2017, 144, 1382-1398.	1.2	133
5 7	A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue. Nature Communications, 2017, 8, 14662.	5.8	30
58	Methylomics of breast cancer: Seeking epimarkers in peripheral blood of young subjects. Tumor Biology, 2017, 39, 101042831769504.	0.8	14
59	Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. European Urology, 2017, 72, 499-506.	0.9	16
60	Rationale for the development of alternative forms of androgen deprivation therapy. Endocrine-Related Cancer, 2017, 24, R275-R295.	1.6	17
61	Investigation of Androgen Receptor Signaling Pathways with Epigenetic Machinery in Prostate Cancer. , 2017, , 205-222.		1
62	Targeting Rabs as a novel therapeutic strategy for cancer therapy. Drug Discovery Today, 2017, 22, 1139-1147.	3.2	46
64	Transcriptional regulation of core autophagy and lysosomal genes by the androgen receptor promotes prostate cancer progression. Autophagy, 2017, 13, 506-521.	4.3	88
65	Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent upâ€regulation of IRF1. Prostate, 2017, 77, 1489-1498.	1.2	14
66	A Prostate Cancer Risk Element Functions as a Repressive Loop that Regulates HOXA13. Cell Reports, 2017, 21, 1411-1417.	2.9	68
67	Exosomal proteins as prostate cancer biomarkers in urine: From mass spectrometry discovery to immunoassay-based validation. European Journal of Pharmaceutical Sciences, 2017, 98, 80-85.	1.9	73
68	Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers, 2017, 9, 22.	1.7	36
69	Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. BMC Cancer, 2017, 17, 759.	1.1	57
70	Proteins regulating the intercellular transfer and function of P-glycoprotein in multidrug-resistant cancer. Ecancermedicalscience, 2017, 11, 768.	0.6	25
71	Evaluation of NKX3.1 and C-MYC expression in canine prostatic cancer. Research in Veterinary Science, 2018, 118, 365-370.	0.9	19
72	Molecular and cellular mechanisms of castration resistant prostate cancer (Review). Oncology Letters, 2018, 15, 6063-6076.	0.8	116
73	GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocrine-Related Cancer, 2018, 25, 453-469.	1.6	48
74	Genes and Pathways Regulated by Androgens in Human Neural Cells, Potential Candidates for the Male Excess in Autism Spectrum Disorder. Biological Psychiatry, 2018, 84, 239-252.	0.7	67

		CITATION REPORT		
#	Article		IF	CITATIONS
75	Insights about genome function from spatial organization of the genome. Human Genor	nics, 2018, 12, 8.	1.4	23
76	Transcriptional Regulation in Prostate Cancer. Cold Spring Harbor Perspectives in Medic a030437.	ne, 2018, 8,	2.9	57
77	The Biological Role of Androgen Receptor in Prostate Cancer Progression. , 2018, , .			1
78	Homeodomain Proteins Directly Regulate ATM Kinase Activity. Cell Reports, 2018, 24, 1	471-1483.	2.9	7
79	Chromatin Landscape Distinguishes the Genomic Loci of Hundreds of Androgen-Recepto LincRNAs From the Loci of Non-associated LincRNAs. Frontiers in Genetics, 2018, 9, 132		1.1	10
80	Novel IncRNA <i>LINC00844</i> Regulates Prostate Cancer Cell Migration and Invasion Signaling. Molecular Cancer Research, 2018, 16, 1865-1878.	through AR	1.5	79
81	Review of applications of high-throughput sequencing in personalized medicine: barriers facilitators of future progress in research and clinical application. Briefings in Bioinforma 20, 1795-1811.		3.2	112
82	Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abirate Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. Neoplasia, 2019, 21, 8		2.3	32
83	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediearly detection. Nature Communications, 2019, 10, 4666.	ction and	5.8	146
84	RAB38 is a potential prognostic factor for tumor recurrence in non‑small cell lung can Letters, 2019, 18, 2598-2604.	cer. Oncology	0.8	8
85	Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nature 2019, 25, 1615-1626.	? Medicine,	15.2	45
86	Integrative Genomic Analysis of OCT1 Reveals Coordinated Regulation of Androgen Rec Advanced Prostate Cancer. Endocrinology, 2019, 160, 463-472.	eptor in	1.4	23
87	Integrated epigenomic analysis stratifies chromatin remodellers into distinct functional g Epigenetics and Chromatin, 2019, 12, 12.	groups.	1.8	23
88	Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cance Cancer Research, 2019, 17, 263-276.	r. Molecular	1.5	27
89	An AR-ERG transcriptional signature defined by long-range chromatin interactomes in pr cells. Genome Research, 2019, 29, 223-235.	ostate cancer	2.4	46
90	The relationship between microRNAs and Rab family GTPases in human cancers. Journal Physiology, 2019, 234, 12341-12352.	of Cellular	2.0	10
91	Lessons from eRNAs: understanding transcriptional regulation through the lens of nasce Transcription, 2020, 11, 3-18.	nt RNAs.	1.7	13
92	SOX2 has dual functions as a regulator in the progression of neuroendocrine prostate ca Laboratory Investigation, 2020, 100, 570-582.	ancer.	1.7	21

#	Article	IF	CITATIONS
93	Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma. Pathobiology, 2020, 87, 30-36.	1.9	9
94	iODA: An integrated tool for analysis of cancer pathway consistency from heterogeneous multi-omics data. Journal of Biomedical Informatics, 2020, 112, 103605.	2.5	10
95	Roles of <i>CCNB2</i> and <i>NKX3-1</i> in Nasopharyngeal Carcinoma. Cancer Biotherapy and Radiopharmaceuticals, 2020, 35, 208-213.	0.7	7
96	The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. International Journal of Molecular Sciences, 2020, 21, 4507.	1.8	289
97	Hexane Insoluble Fraction from Purple Rice Extract Retards Carcinogenesis and Castration-Resistant Cancer Growth of Prostate Through Suppression of Androgen Receptor Mediated Cell Proliferation and Metabolism. Nutrients, 2020, 12, 558.	1.7	5
98	A review of the effects and molecular mechanisms of dimethylcurcumin (ASCâ€J9) on androgen receptorâ€related diseases. Chemical Biology and Drug Design, 2021, 97, 821-835.	1.5	14
99	microRNAâ€146a and â€155, upregulated by periodontitis and type 2 diabetes in oral fluids, are predicted to regulate SARSâ€CoVâ€2 oral receptor genes. Journal of Periodontology, 2021, 92, 35-43.	1.7	34
100	The Role of Nkx3.1 in Cancers and Stemness. International Journal of Stem Cells, 2021, 14, 168-179.	0.8	7
101	The helix-loop-helix transcriptional regulator Id4 is required for terminal differentiation of luminal epithelial cells in the prostate. Oncoscience, 2021, 8, 14-30.	0.9	0
102	The Emerging Clinical Role of Spermine in Prostate Cancer. International Journal of Molecular Sciences, 2021, 22, 4382.	1.8	15
103	Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis. Current Pharmaceutical Design, 2021, 27, 989-995.	0.9	6
104	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1167-1180.	2.0	4
105	Oncogenic role of PinX1 in prostate cancer cells through androgen receptor dependent and independent mechanisms. Journal of Steroid Biochemistry and Molecular Biology, 2021, 210, 105858.	1.2	1
106	LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. Seminars in Cancer Biology, 2022, 82, 120-133.	4.3	14
107	Neural Transcription Factors in Disease Progression. Advances in Experimental Medicine and Biology, 2019, 1210, 437-462.	0.8	2
108	The Role of Androgen-Regulated Long Noncoding RNAs in Prostate Cancer. , 2015, , 191-210.		2
111	Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. Journal of Clinical Investigation, 2019, 129, 4492-4505.	3.9	250
112	Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. Journal of Clinical Investigation, 2012, 122, 2469-2481.	3.9	89

#	Article	IF	CITATIONS
113	Systems analysis of the prostate tumor suppressor NKX3.1 supports roles in DNA repair and luminal cell differentiation. F1000Research, 2014, 3, 115.	0.8	9
114	Analysis of Aurora kinases genes expression points on their distinct roles in prostate cancer development. Ukrainian Biochemical Journal, 2019, 91, 15-26.	0.1	1
115	Identification and validation of regulatory SNPs that modulate transcription factor chromatin binding and gene expression in prostate cancer. Oncotarget, 2016, 7, 54616-54626.	0.8	41
116	Molecular pathways and targets in prostate cancer. Oncotarget, 2014, 5, 7217-7259.	0.8	84
117	A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor. Anti-Cancer Agents in Medicinal Chemistry, 2015, 15, 1333-1340.	0.9	15
118	Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer. Anticancer Research, 2017, 37, 125-134.	0.5	25
119	Androgen receptor genomic regulation. Translational Andrology and Urology, 2013, 2, 157-177.	0.6	63
120	Genomeâ€wide identification of CpG island methylator phenotype related gene signature as a novel prognostic biomarker of gastric cancer. PeerJ, 2020, 8, e9624.	0.9	11
121	Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression. Oncogene, 2021, 40, 6479-6493.	2.6	10
122	Selective and Classical Androgen Response Elements in Androgen-Regulated Gene Expression. , 2013, , 13-27.		0
125	NKX3.1 versus cyclin D1 expression in prostatic adenocarcinoma. Egyptian Journal of Pathology, 2017, 37, 306-314.	0.0	0
126	MSH2 is Inactivated by Multiple Mechanisms in Prostate Tumors, Leading to a Distinct Immune Response and Clinical Outcome Compared to MSH2 Deficient Colorectal Cancer. SSRN Electronic Journal, 0, , .	0.4	0
128	Small GTPase Rab3B: biological properties and possible role in carcinogenesis. Uspehi Molekularnoj Onkologii, 2019, 5, 78-85.	0.1	1
129	Anti-metastatic effect of GV1001 on prostate cancer cells; roles of GnRHR-mediated Gαs-cAMP pathway and AR-YAP1 axis. Cell and Bioscience, 2021, 11, 191.	2.1	4
131	Synthesis and crystal structures of D-annulated pentacyclic steroids: looking within and beyond AR signalling in prostate cancer CrystEngComm, 0, , .	1.3	1
132	Gene of the month: NKX3.1. Journal of Clinical Pathology, 2022, 75, 361-364.	1.0	7
133	Androgen Receptor-Mediated Transcription in Prostate Cancer. Cells, 2022, 11, 898.	1.8	14
134	Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells. BMC Cancer, 2022, 22, 260.	1.1	10

#	Article	IF	CITATIONS
135	Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy. Cancer Letters, 2022, 534, 215619.	3.2	18
136	Targeting Mitochondrial OXPHOS and Their Regulatory Signals in Prostate Cancers. International Journal of Molecular Sciences, 2021, 22, 13435.	1.8	15
149	Encoding gene RAB3B exists in linear chromosomal and circular extrachromosomal DNA and contributes to cisplatin resistance of hypopharyngeal squamous cell carcinoma via inducing autophagy. Cell Death and Disease, 2022, 13, 171.	2.7	37
150	The role of epigenetics in cancer metastasis. , 2022, , 277-300.		0
151	Comprehensive Expression Profile Analysis of Neutrophil Extracellular Trap-Affected Genes in Gastric Cancer Cells and the Clinical Significance of IncRNA NEAT1-Related Signaling. Frontiers in Oncology, 2022, 12, .	1.3	3
153	The Potential Role of Exosomal Proteins in Prostate Cancer. Frontiers in Oncology, 0, 12, .	1.3	7
154	<scp>TRIM33</scp> drives prostate tumor growth by stabilizing androgen receptor from Skp2â€mediated degradation. EMBO Reports, 2022, 23, .	2.0	9
155	FOXA1 in prostate cancer. Asian Journal of Andrology, 2023, 25, 287-295.	0.8	4
156	Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 4714.	1.7	0
157	RAB3D, upregulated by aryl hydrocarbon receptor (AhR), promotes the progression of prostate cancer by activating the PI3K/AKT signaling pathway. Cell Biology International, 2022, 46, 2246-2256.	1.4	3
160	Transcription networks rewire gene repertoire to coordinate cellular reprograming in prostate cancer. Seminars in Cancer Biology, 2023, 89, 76-91.	4.3	5
161	The Role of Rab GTPases in the development of genetic and malignant diseases. Molecular and Cellular Biochemistry, 2024, 479, 255-281.	1.4	1